13 May 2024
13 May 2024
The Phase III trial pitted Opdivo and Yervoy combination therapy with chemoradiation against AstraZeneca’s Imfinzi and chemoradiation therapy.
Keeping high-qualified, experienced clinical trial staff on board plays a crucial role in bringing new drugs to market. Dana Durkan of KPS Life discusses how to avoid fraudulent staff, navigate work from home dynamics, and keep hold of your most valued employees.
The Clinical Trials Arena team evaluates assets in oncology and metabolic disorders.
Caudrion said the Phase IIa trial has proved that targeting PDE9 activates the NP signalling pathway.
Currently, there is no legislation or guidance to tell those in the industry how to run cross-border trials in Europe.
Refreshgene announced data at the ASCGT Conference 2024 where Regeneron also boasted positive data in a gene therapy hearing loss trial.
RAPT is closing two Phase II trials for Rapt’s lead candidate, zelnecirnon, three months after the FDA placed a clinical hold on them.
The positive Phase I/II data has supported a RMAT designation from the FDA and a PRIME designation by the EMA.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
GlobalData's latest report offers a data-driven overview of the current and future competitive landscape in AV therapeutics. Our epidemiologists estimated more than 403 million diagnosed prevalent cases of AV in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for AV. The R&D activity is moderate within the AV space, with total 13 molecules present in the late-stage pipeline. The US is emerging as the key country for conducting AV trials.
GlobalData's latest report offers a data-driven overview of the current and future competitive landscape in AV therapeutics. Our epidemiologists estimated more than 403 million diagnosed prevalent cases of AV in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for AV. The R&D activity is moderate within the AV space, with total 13 molecules present in the late-stage pipeline. The US is emerging as the key country for conducting AV trials.
GlobalData's latest report offers a data-driven overview of the current and future competitive landscape in AV therapeutics. Our epidemiologists estimated more than 403 million diagnosed prevalent cases of AV in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for AV. The R&D activity is moderate within the AV space, with total 13 molecules present in the late-stage pipeline. The US is emerging as the key country for conducting AV trials.
GlobalData's latest report offers a data-driven overview of the current and future competitive landscape in AV therapeutics. Our epidemiologists estimated more than 403 million diagnosed prevalent cases of AV in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for AV. The R&D activity is moderate within the AV space, with total 13 molecules present in the late-stage pipeline. The US is emerging as the key country for conducting AV trials.
GlobalData's latest report offers a data-driven overview of the current and future competitive landscape in AV therapeutics. Our epidemiologists estimated more than 403 million diagnosed prevalent cases of AV in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for AV. The R&D activity is moderate within the AV space, with total 13 molecules present in the late-stage pipeline. The US is emerging as the key country for conducting AV trials.
Give your business an edge with our leading industry insights.
